C-reactive protein and the risk of cancer: a mendelian randomization study

Research output: Contribution to journalJournal articleResearchpeer-review

Elevated plasma levels of C-reactive protein (CRP), a marker of inflammation, are associated with an increased risk of cancer, but it is unclear whether this association is causal. We examined whether four common single-nucleotide polymorphisms (SNPs) in the CRP gene that are associated with altered plasma CRP levels are causally associated with an increased risk of cancer. The study population included participants in a prospective study (n = 10 215) and a cross-sectional study (n = 36 403) of the adult general population in Denmark, all of whom were genotyped for the CRP SNPs. The association between plasma CRP levels measured by a high-sensitivity turbidimetry assay and the risk of cancer was examined for 8224 participants in the prospective study. The hazard ratio of cancer for a doubling of the plasma CRP level was 1.09 (95% confidence interval [CI] = 1.03 to 1.14). The nine most common genotype combinations of the four CRP SNPs were associated with up to a 72% increase (95% CI = 58% to 87%) in CRP levels but not with an increased risk of cancer. The estimated causal odds ratio for cancer associated with a genetically induced doubling in CRP level was 0.94 (95% CI = 0.81 to 1.08). This finding suggests that elevated CRP levels do not cause cancer.
Original languageEnglish
JournalNational Cancer Institute. Journal (Print)
Issue number3
Pages (from-to)202-6
Number of pages4
Publication statusPublished - 2010

Bibliographical note

Keywords: Adult; Aged; C-Reactive Protein; Cross-Sectional Studies; Denmark; Female; Genotype; Humans; Inflammation; Male; Mendelian Randomization Analysis; Middle Aged; Neoplasms; Odds Ratio; Polymorphism, Single Nucleotide; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Tumor Markers, Biological

ID: 34152019